FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Doyle Noah
2. Date of Event Requiring Statement (Month/Day/Year)
06/24/2015
3. Issuer Name and Ticker or Trading Symbol
RITTER PHARMACEUTICALS INC [RTTR]
(Last)
(First)
(Middle)
RITTER PHARMACEUTICALS, INC., 1801 CENTURY PARK EAST, #1820
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

LOS ANGELES,, CA 90067
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant   (1)   (2) Common Stock 322,753 $ 9.3 (3) I by Javelin Venture Partners I SPV I, LLC (4)
Warrant   (1)   (2) Common Stock 83,224 $ 9.3 (5) I by Javelin Venture Partners, L.P. (6)
Convertible Preferred Stock   (1)   (7) Common Stock 322,753 $ (7) I by Javelin Venture Partners I SPV I, LLC (4)
Convertible Preferred Stock   (1)   (7) Common Stock 1,247,804 $ (7) I by Javelin Venture Partners, L.P. (6)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Doyle Noah
RITTER PHARMACEUTICALS, INC.
1801 CENTURY PARK EAST, #1820
LOS ANGELES,, CA 90067
  X      

Signatures

/s/Andrew J. Ritter, attorney-in-fact 06/24/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Currently exercisable.
(2) This warrant shall be exercisable until the earliest to occur of (a) the date that is seven (7) years from the issue date of the reporting person's warrant or (b) immediately prior to the consummation of a Change of Control Transaction (as defined in the reporting person's warrant) in which the consideration to the Issuer (or its stockholders) consists of cash or freely and immediately tradable securities.
(3) This price is subject to adjustment from time to time pursuant to the provisions of the Javelin Venture Partners I SPV I, LLC Common Stock Purchase Warrant.
(4) As the managing director of Javelin Venture Partners I SPV I, LLC, the reporting person may be deemed the beneficial owner of these shares. The reporting person expressly disclaims beneficiall ownership over these shares except to the extent of his pecuniary interest therein.
(5) This price is subject to adjustment from time to time pursuant to the provisions of the Javelin Venture Partners, L.P. Common Stock Purchase Warrant.
(6) As the managing director of Javelin Venture Partners, L.P. the reporting person may be deemed the beneficial owner of these shares. The reporting person expressly disclaims beneficiall ownership over these shares except to the extent of his pecuniary interest therein.
(7) The Convertible Preferred Stock has no expiration date. Effective on the date of the closing of the Issuer's initial public offering, the Convertible Preferred Stock will automatically convert into Common Stock of the Issuer on a one-for-one basis.
 
Remarks:
Exhibit List: Exhibit 24-Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.